Check the time stamp on this data. Updated AI-Generated Signals for Collegium Pharmaceutical Inc. (COLL) available here: COLL ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

China Resources Pharmaceutical Group (CR Pharmaceutical) has teamed up with the Hong Kong government’s Nano and Advanced Materials Institute (NAMI) to research the repurposing of a cancer drug ...

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx ...

Collegium Pharma (COLL) reported Q1 EPS of ($0.39), $1.29 worse than the analyst estimate of $0.90. Revenue for the quarter came in at $83.8 million versus the consensus estimate ...

HC Wainwright reiterated their buy rating on shares of Collegium Pharmaceutical (NASDAQ:COLL – Free Report) in a research report report published on Friday,Benzinga reports. They currently have a $50.

NASDAQ:COLL opened at $32.91 on Monday. The stock’s 50-day moving average is $30.56 and its 200-day moving average is $34.08. Collegium Pharmaceutical has a 1-year low of $28.39 and a 1-year ...

In December 2024, the collegium met candidates for high court judgeships in Rajasthan, Allahabad and Bombay to assess their suitability for elevation It will be a working holiday for the top three ...

Fintel reports that on January 10, 2025, Needham upgraded their outlook for Collegium Pharmaceutical (NasdaqGS:COLL) from Hold to Buy. Analyst Price Forecast Suggests 29.26% Upside As of December ...

Collegium's 2025 guidance surpasses estimates with projected sales of $735-$750M and adjusted EBITDA of $435-$450M. Analyst highlights growth potential from Jornay PM and strong pain portfolio ...

In a report released today, Serge Belanger from Needham upgraded Collegium Pharmaceutical (COLL – Research Report) to a Buy, with a price target of $46.00. Discover outperforming stocks and ...